1. Home
  2. AVDL vs AMRC Comparison

AVDL vs AMRC Comparison

Compare AVDL & AMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • AMRC
  • Stock Information
  • Founded
  • AVDL 2015
  • AMRC 2000
  • Country
  • AVDL Ireland
  • AMRC United States
  • Employees
  • AVDL N/A
  • AMRC N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • AMRC Engineering & Construction
  • Sector
  • AVDL Health Care
  • AMRC Consumer Discretionary
  • Exchange
  • AVDL Nasdaq
  • AMRC Nasdaq
  • Market Cap
  • AVDL 861.4M
  • AMRC 869.5M
  • IPO Year
  • AVDL 1996
  • AMRC 2010
  • Fundamental
  • Price
  • AVDL $10.83
  • AMRC $18.30
  • Analyst Decision
  • AVDL Strong Buy
  • AMRC Hold
  • Analyst Count
  • AVDL 7
  • AMRC 7
  • Target Price
  • AVDL $18.71
  • AMRC $18.86
  • AVG Volume (30 Days)
  • AVDL 1.6M
  • AMRC 684.8K
  • Earning Date
  • AVDL 08-07-2025
  • AMRC 08-04-2025
  • Dividend Yield
  • AVDL N/A
  • AMRC N/A
  • EPS Growth
  • AVDL N/A
  • AMRC N/A
  • EPS
  • AVDL N/A
  • AMRC 1.03
  • Revenue
  • AVDL $194,450,000.00
  • AMRC $1,824,351,000.00
  • Revenue This Year
  • AVDL $56.86
  • AMRC $8.59
  • Revenue Next Year
  • AVDL $30.45
  • AMRC $9.78
  • P/E Ratio
  • AVDL N/A
  • AMRC $17.84
  • Revenue Growth
  • AVDL 252.64
  • AMRC 30.13
  • 52 Week Low
  • AVDL $6.38
  • AMRC $8.49
  • 52 Week High
  • AVDL $17.30
  • AMRC $39.68
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 72.02
  • AMRC 68.32
  • Support Level
  • AVDL $8.74
  • AMRC $17.31
  • Resistance Level
  • AVDL $9.56
  • AMRC $19.87
  • Average True Range (ATR)
  • AVDL 0.41
  • AMRC 1.03
  • MACD
  • AVDL 0.18
  • AMRC 0.15
  • Stochastic Oscillator
  • AVDL 89.88
  • AMRC 70.84

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About AMRC Ameresco Inc.

Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.

Share on Social Networks: